Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting

Summary by AI BETAClose X

Vivoryon Therapeutics N.V. announced that all items on the agenda were approved at its 2026 Annual General Meeting, including the appointment of Marcus Irsfeld as CFO and the re-appointment of Dr. Frank Weber and Dr. Michael Schaeffer as executive directors. The company, focused on developing medicines for inflammatory and fibrotic disorders, particularly kidney diseases, made these announcements on September 29, 2026.

Disclaimer*

UK 100

Latest directors dealings